Success Metrics

Clinical Success Rate
95.3%

Based on 182 completed trials

Completion Rate
95%(182/191)
Active Trials
9(4%)
Results Posted
31%(56 trials)
Terminated
9(4%)

Phase Distribution

Ph phase_1
127
57%
Ph phase_3
26
12%
Ph not_applicable
11
5%
Ph phase_4
33
15%
Ph early_phase_1
7
3%
Ph phase_2
17
8%

Phase Distribution

134

Early Stage

17

Mid Stage

59

Late Stage

Phase Distribution221 total trials
Early Phase 1First-in-human
7(3.2%)
Phase 1Safety & dosage
127(57.5%)
Phase 2Efficacy & side effects
17(7.7%)
Phase 3Large-scale testing
26(11.8%)
Phase 4Post-market surveillance
33(14.9%)
N/ANon-phased studies
11(5.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.0%

182 of 200 finished

Non-Completion Rate

9.0%

18 ended early

Currently Active

9

trials recruiting

Total Trials

223

all time

Status Distribution
Active(9)
Completed(182)
Terminated(18)
Other(14)

Detailed Status

Completed182
unknown14
Terminated9
Withdrawn9
Recruiting8
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
223
Active
9
Success Rate
95.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 17 (3.2%)
Phase 1127 (57.5%)
Phase 217 (7.7%)
Phase 326 (11.8%)
Phase 433 (14.9%)
N/A11 (5.0%)

Trials by Status

terminated94%
recruiting84%
unknown146%
withdrawn94%
active_not_recruiting10%
completed18282%

Recent Activity

Clinical Trials (223)

Showing 20 of 223 trialsScroll for more
NCT05646862Phase 3

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Active Not Recruiting
NCT06114836Not Applicable

GERD Infant Feeding Therapeutics Trial (GIFT Trial)

Recruiting
NCT07214662Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Recruiting
NCT06686628Phase 1

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Completed
NCT02783040Phase 1

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Completed
NCT07223671Phase 1

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

Completed
NCT06562907Phase 1

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

Recruiting
NCT06378398Early Phase 1

A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy

Completed
NCT07235748Phase 1

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Completed
NCT05517928Not Applicable

A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

Recruiting
NCT04930991Early Phase 1

High Dose Omeprazole in Patients With Pancreatic Cancer

Recruiting
NCT05891119Early Phase 1

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Completed
NCT05444556Phase 1

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Completed
NCT04840888Phase 1

A Study of LY3484356 in Healthy Female Participants

Completed
NCT02950259Phase 1

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Completed
NCT06494761Phase 1

A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body

Completed
NCT07156201Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years

Recruiting
NCT07149415Phase 1

A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55

Completed
NCT05468164Phase 1

A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants

Completed
NCT05741385Not Applicable

A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
223